Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2021-08-03 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document explicitly uses the header "Directors’ Dealings" and contains detailed information regarding a transaction (Acquisition) by a person discharging managerial responsibilities (Member of the managing body, Sung Lee). This directly corresponds to the definition of Director's Dealing reports, which are classified under the code DIRS.
2021-08-03 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details the acquisition/disposal of shares resulting in a change in voting rights percentage (3.91%) held by Royalty Pharma PLC in MorphoSys AG. This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns with the Major Shareholding Notification category (MRQ). Although the header mentions 'Voting Rights Announcements', the content is specifically about crossing a major holding threshold, making MRQ more precise than DVA (Declaration of Voting Results).
2021-08-02 English
Declaration of Voting Results & Voting Rights Announcements 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details changes in voting rights percentages (crossing a threshold of 3.91%) held by an individual (Pablo Legorreta) and an associated entity (Royalty Pharma Investments 2019 ICAV). This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the disclosure of a major holding change, making MRQ more specific than DVA (Declaration of Voting Results) or RNS (General Regulatory Filing).
2021-08-02 English
Correction of a release from 30/07/2021, 14:30 CET/CEST - MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'Total Voting Rights Announcement' which is a correction to a previous release. It explicitly mentions Article 41 of the WpHG (German Securities Trading Act) and details a 'Type of capital measure' including 'Conditional capital increase' and 'Other capital measure'. This type of announcement, dealing with changes in the total number of voting rights due to capital structure events, fits best under the 'Share Issue/Capital Change' category (SHA). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it pertains specifically to capital structure changes.
2021-08-02 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section labeled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Krisja Vermeylen), their position ('Member of the administrative or supervisory body'), the nature of the transaction ('Acquisition'), price, volume, and date. This content directly matches the definition for Director's Dealing.
2021-07-30 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' and details a 'Type of capital measure' including 'Conditional capital increase' and 'Other capital measure' under German Securities Trading Act (WpHG) references. This content directly relates to changes in the company's capital structure or voting rights, which aligns best with the 'Capital/Financing Update' (CAP) category, as it details a capital measure affecting voting rights. While it is a regulatory announcement (RNS), the specific nature of the capital measure makes CAP a more precise fit than the general RNS fallback. It is not a standard 10-K, ER, or IR. Given the focus on capital structure change, CAP is the most appropriate classification.
2021-07-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.